Divi's Laboratories Limited vs Parenteral Drugs (India) Ltd
A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and Parenteral Drugs (India) Ltd (PDPL) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Divi's Laboratories Limited leads DIVISLAB vs PDPL on 10 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability40
- Growth10
- Size & financial health30
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
DIVISLAB takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
DIVISLAB takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
DIVISLAB takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
- − ["Stock is trading at 14.60 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
- + ["Company has reduced debt."]
- − ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of -48.3% over past five years.", "Contingent liabilities of Rs.135 Cr.", "Company's cost of borrowing seems high"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.